BSE Live
Mar 23, 16:01Prev. Close
82.95
Open Price
84.80
Bid Price (Qty.)
83.20 (100)
Offer Price (Qty.)
86.25 (29)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Godavari Drugs (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | |
| Diluted EPS (Rs.) | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | |
| Cash EPS (Rs.) | 9.07 | 10.02 | 7.61 | 9.22 | 7.11 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 57.56 | 51.74 | 44.38 | 39.35 | 32.38 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 57.56 | 51.74 | 44.38 | 39.35 | 32.38 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 150.52 | 208.10 | 211.97 | 213.94 | 162.90 | |
| PBDIT/Share (Rs.) | 17.00 | 18.49 | 14.04 | 15.36 | 13.59 | |
| PBIT/Share (Rs.) | 13.75 | 15.84 | 11.46 | 13.11 | 11.97 | |
| PBT/Share (Rs.) | 7.47 | 9.19 | 6.55 | 9.32 | 7.58 | |
| Net Profit/Share (Rs.) | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 11.29 | 8.88 | 6.62 | 7.17 | 8.34 | |
| PBIT Margin (%) | 9.13 | 7.61 | 5.40 | 6.12 | 7.34 | |
| PBT Margin (%) | 4.96 | 4.41 | 3.09 | 4.35 | 4.65 | |
| Net Profit Margin (%) | 3.86 | 3.54 | 2.37 | 3.25 | 3.36 | |
| Return on Networth / Equity (%) | 10.10 | 14.24 | 11.32 | 17.70 | 16.92 | |
| Return on Capital Employed (%) | 14.79 | 22.60 | 18.08 | 22.61 | 22.18 | |
| Return on Assets (%) | 3.06 | 4.11 | 3.11 | 5.17 | 4.52 | |
| Total Debt/Equity (X) | 1.42 | 1.43 | 1.00 | 0.69 | 1.15 | |
| Asset Turnover Ratio (%) | 0.82 | 1.22 | 1.43 | 1.67 | 134.59 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.08 | 1.08 | 1.18 | 1.29 | 1.34 | |
| Quick Ratio (X) | 0.70 | 0.83 | 0.91 | 1.11 | 1.05 | |
| Inventory Turnover Ratio (X) | 4.67 | 6.02 | 9.22 | 10.37 | 8.37 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 125.12 | 123.00 | 87.45 | 67.32 | 60.89 | |
| EV/Net Operating Revenue (X) | 1.10 | 0.78 | 0.55 | 0.42 | 0.50 | |
| EV/EBITDA (X) | 9.77 | 8.83 | 8.27 | 5.82 | 5.95 | |
| MarketCap/Net Operating Revenue (X) | 0.58 | 0.45 | 0.36 | 0.31 | 0.28 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 1.52 | 1.80 | 1.71 | 1.66 | 1.41 | |
| Price/Net Operating Revenue | 0.58 | 0.45 | 0.36 | 0.31 | 0.28 | |
| Earnings Yield | 0.07 | 0.08 | 0.07 | 0.11 | 0.12 |
25.02.2026
Godavari Drugs Standalone December 2025 Net Sales at Rs 22.18 crore, down 24.93% Y-o-Y
24.11.2025
Godavari Drugs Standalone September 2025 Net Sales at Rs 26.65 crore, up 2.15% Y-o-Y
10.06.2025
Godavari Drugs Standalone March 2025 Net Sales at Rs 25.50 crore, down 34% Y-o-Y
17.02.2025
Godavari Drugs Standalone December 2024 Net Sales at Rs 29.55 crore, down 31.45% Y-o-Y
25.02.2026
Godavari Drugs Standalone December 2025 Net Sales at Rs 22.18 crore, down 24.93% Y-o-Y
24.11.2025
Godavari Drugs Standalone September 2025 Net Sales at Rs 26.65 crore, up 2.15% Y-o-Y
10.06.2025
Godavari Drugs Standalone March 2025 Net Sales at Rs 25.50 crore, down 34% Y-o-Y
17.02.2025
Godavari Drugs Standalone December 2024 Net Sales at Rs 29.55 crore, down 31.45% Y-o-Y
23.03.2026
Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally
23.03.2026
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth